Medtronic Plc (NYSE:MDT) Receives Average Rating of "Hold" From Analysts
Medtronic Plc (NYSE:MDT) Receives Average Rating of "Hold" From Analysts
Medtronic plc (NYSE:MDT – Get Rating) has received an average rating of "Hold" from the twenty-four research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, eleven have given a hold rating and five have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $91.78.
據MarketBeat.com報道，美敦力(紐約證券交易所代碼：MDT-GET Rating)從目前覆蓋該公司的24家研究機構那裏獲得了“持有”的平均評級。一名分析師對該股的評級為賣出，11名分析師給出了持有評級，5名分析師給出了該公司的買入評級。在過去一年對該股進行評級的經紀商中，1年目標價的平均水平為91.78美元。
A number of analysts recently commented on the company. Oppenheimer lowered Medtronic from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $106.00 to $85.00 in a research report on Wednesday, November 23rd. Mizuho lowered their price target on Medtronic from $100.00 to $95.00 and set a "buy" rating for the company in a research note on Tuesday, January 24th. Barclays decreased their price objective on shares of Medtronic from $90.00 to $85.00 and set an "equal weight" rating for the company in a report on Friday, November 25th. Cowen cut their target price on shares of Medtronic from $117.00 to $90.00 in a report on Wednesday, November 23rd. Finally, Royal Bank of Canada lowered shares of Medtronic from an "outperform" rating to a "sector perform" rating and decreased their price target for the company from $102.00 to $89.00 in a report on Monday, January 9th.
一些分析師最近對該公司發表了評論。奧本海默在11月23日(週三)的一份研究報告中將美敦力的評級從“跑贏大盤”下調至“市場表現”，並將美敦力的股票目標價從106.00美元下調至85美元。瑞穗在1月24日週二的一份研究報告中將美敦力的目標價從100.00美元下調至95美元，並將該公司的評級定為“買入”。巴克萊在11月25日星期五的一份報告中將美敦力股票的目標價從90.00美元下調至85.00美元，併為該公司設定了“同等權重”的評級。考恩在11月23日週三的一份報告中將美敦力股票的目標價從117.00美元下調至90美元。最後，加拿大皇家銀行在1月9日週一的一份報告中將美敦力的股票評級從“跑贏大盤”下調至“行業表現”，並將該公司的目標價從102.00美元下調至89美元。
Medtronic Trading Up 0.9 %
美敦力股價上漲0.9%
MDT stock opened at $82.58 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.41 and a debt-to-equity ratio of 0.40. The firm has a market cap of $109.85 billion, a P/E ratio of 25.65, a P/E/G ratio of 2.01 and a beta of 0.72. Medtronic has a 1-year low of $75.76 and a 1-year high of $114.31. The business's 50 day moving average is $78.93 and its 200-day moving average is $84.49.
MDT股價週五開盤報82.58美元。該公司的流動比率為1.76，速動比率為1.41，債務權益比率為0.40。該公司市值為1,098.5億美元，市盈率為25.65倍，市盈率為2.01倍，貝塔係數為0.72。美敦力的一年低點為75.76美元，一年高位為114.31美元。該業務的50日移動均線切入位在78.93美元，200日移動均線切入位在84.49美元。
Medtronic Dividend Announcement
美敦力股息公告
The company also recently declared a quarterly dividend, which was paid on Friday, January 13th. Shareholders of record on Wednesday, December 21st were issued a $0.68 dividend. The ex-dividend date was Tuesday, December 20th. This represents a $2.72 annualized dividend and a yield of 3.29%. Medtronic's payout ratio is currently 84.47%.
該公司最近還宣佈了季度股息，股息於1月13日星期五支付。12月21日(星期三)登記在冊的股東獲得了0.68美元的股息。除息日期是12月20日，星期二。這意味着年化股息為2.72美元，收益率為3.29%。美敦力的派息率目前為84.47%。
Insider Buying and Selling
內幕買賣
In other news, EVP Sean Salmon sold 16,631 shares of the stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $80.50, for a total value of $1,338,795.50. Following the completion of the sale, the executive vice president now owns 36,088 shares in the company, valued at $2,905,084. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.29% of the stock is owned by company insiders.
在其他新聞方面，執行副總裁肖恩·薩蒙在12月13日星期二的交易中出售了16,631股該股。這些股票的平均價格為80.50美元，總價值為1,338,795.50美元。出售完成後，執行副總裁總裁現在擁有該公司36,088股股份，價值2905,084美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過美國證券交易委員會網站。0.29%的股份由公司內部人士持有。
Hedge Funds Weigh In On Medtronic
對衝基金看好美敦力
Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDT. Bivin & Associates Inc. raised its position in Medtronic by 1.1% during the 2nd quarter. Bivin & Associates Inc. now owns 9,785 shares of the medical technology company's stock valued at $878,000 after purchasing an additional 110 shares during the last quarter. Abbrea Capital LLC lifted its stake in Medtronic by 1.7% during the 2nd quarter. Abbrea Capital LLC now owns 6,632 shares of the medical technology company's stock valued at $600,000 after acquiring an additional 112 shares during the period. HighTower Trust Services LTA increased its position in shares of Medtronic by 2.4% during the 2nd quarter. HighTower Trust Services LTA now owns 4,819 shares of the medical technology company's stock valued at $424,000 after purchasing an additional 113 shares during the last quarter. Hotaling Investment Management LLC increased its position in shares of Medtronic by 0.6% during the 2nd quarter. Hotaling Investment Management LLC now owns 20,675 shares of the medical technology company's stock valued at $1,856,000 after purchasing an additional 114 shares during the last quarter. Finally, Bank of Stockton increased its holdings in Medtronic by 1.2% in the 2nd quarter. Bank of Stockton now owns 10,058 shares of the medical technology company's stock worth $903,000 after acquiring an additional 115 shares in the last quarter. 80.37% of the stock is currently owned by hedge funds and other institutional investors.
幾家對衝基金和其他機構投資者最近增持或減持了MDT的股份。Bivin&Associates Inc.在第二季度將其在美敦力的持倉提高了1.1%。Bivin&Associates Inc.現在持有這家醫療技術公司9,785股股票，價值87.8萬美元，上個季度又購買了110股。Abbrea Capital LLC在第二季度增持了1.7%的美敦力股份。Abbrea Capital LLC在此期間又收購了112股，現在擁有6632股這家醫療技術公司的股票，價值60萬美元。HighTower Trust Services LTA在第二季度將其在美敦力股票的持倉增加了2.4%。HighTower Trust Services LTA現在擁有這家醫療技術公司4819股股票，價值42.4萬美元，上個季度又購買了113股。Hotaling Investment Management LLC在第二季度將其在美敦力股票的持倉增加了0.6%。Hotaling Investment Management LLC現在擁有這家醫療技術公司20,675股股票，價值1,856,000美元，此前在上個季度又購買了114股。最後，斯托克頓銀行在第二季度增持了1.2%的美敦力股份。斯托克頓銀行現在持有這家醫療技術公司10058股股票，價值90.3萬美元，上個季度又購買了115股。80.37%的股票目前由對衝基金和其他機構投資者持有。
About Medtronic
美敦力簡介
(Get Rating)
(獲取評級)
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit.
美敦力是一家醫療科技公司，從事基於設備的醫療治療和服務的開發、製造、分銷和銷售。它通過以下部門運作：心血管Porrtfolio、神經科學投資組合、醫療外科投資組合和糖尿病運營部門。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Medtronic (MDT)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免費獲取StockNews.com關於美敦力(MDT)的研究報告
- 市場回顧周-1/23-1/27
- 為什麼Lucid在一天內飆升了近100%
- 利用這些鐵路股票實現增長和收入
- ASML預計今年芯片需求回升，提振銷售觀點
- KLA公司：在動盪不安的半市場中站穩腳跟
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
接受美敦力日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對美敦力及相關公司評級的每日摘要。